MétaCan
Menu
← Back to cohort

S923 Clostridium difficile Infection in Patients Treated With Tofacitinib in the Ulcerative Colitis Clinical Program

2021· article· en· W3208492892 on OpenAlexaff
Edward V. Loftus, Alessandro Armuzzi, Daniel C. Baumgart, K Gecse, Susan B. Connelly, Chinyu Su, Kenneth Kwok, Xiang Guo, Jami Kinnucan

Bibliographic record

VenueThe American Journal of Gastroenterology · 2021
Typearticle
Languageen
FieldMedicine
TopicClostridium difficile and Clostridium perfringens research
Canadian institutionsUniversity of Alberta
Fundersnot available
KeywordsTofacitinibMedicineUlcerative colitisInternal medicineClostridium difficileCohortGastroenterologyIncidence (geometry)SurgeryRheumatoid arthritisAntibioticsMicrobiology

Abstract

fetched live from OpenAlex

Introduction: Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. Patients (pts) with UC are susceptible to C. difficile infection (CDI).1,2 In the tofacitinib UC clinical program, previous analyses showed CDI rates to be similar/numerically lower among tofacitinib-treated than PBO-treated pts.3 Here, we present an updated analysis of CDI in the tofacitinib UC clinical program, incl. final data from the completed open-label, long-term extension (OLE) study (as of Aug 24, 2020). Methods: CDI events were evaluated from 4 randomized, PBO-controlled studies (1 Phase (P)2 & 2 P3 induction studies [NCT00787202;NCT01465763;NCT01458951]; 1 maintenance P3 study [NCT01458574]) and 1 OLE study (NCT01470612), as 3 cohorts: Induction (P2/P3 induction), Maintenance (P3 maintenance), and Overall (pts receiving ≥ 1 dose of tofacitinib 5 or 10 mg BID in P2/P3/OLE studies). Pts in the Overall Cohort were analyzed by predominant dose (PD; 5 or 10 mg BID based on average daily dose < 15 mg or ≥ 15 mg, respectively). Proportions and incidence rates (IRs; unique pts with events per 100 pt-years [PY] of exposure) of CDI were evaluated. All pts had CDI screening; a positive test excluded pts from program entry. Results: The Overall Cohort comprised 1,157 pts who received ≥ 1 dose of tofacitinib 5 or 10 mg BID, representing 776.4 PY and 2,038.0 PY, respectively, of tofacitinib exposure and ≤ 7.8 years of treatment. 82.6% of pts received PD 10 mg BID. Induction and Maintenance Cohort CDI IRs were reported previously (Table 1). In the Overall Cohort, 9 pts had CDI (all PD 10 mg BID; Table 1); events were mild in 4 pts and moderate in 5. 6 pts continued study treatment without interruption; 3 discontinued (1 temporarily; 2 permanently). CDI resolved with treatment in 8 pts and was still present in 1 at the time of study discontinuation. 2 events were reported as serious AEs due to hospitalization. 8 pts with CDI had no prior history of CDI. 5 pts were receiving 5-ASA and 1 was receiving 5-ASA/corticosteroids when the CDI occurred. Conclusion: In the UC clinical program, CDI IRs among pts receiving tofacitinib were low and generally similar to those reported for vedolizumab in UC,2 similar to/lower than among all pts with IBD,4 and in this analysis remained stable since the previous data cut.3Table 1.: IRs of CDI Among Pts in the Induction, Maintenance, and Overall Cohorts

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.016

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.002
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0050.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.023
GPT teacher head0.332
Teacher spread0.309 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueThe American Journal of Gastroenterology→Same topicClostridium difficile and Clostridium perfringens research→French-language works237,207→